

KEVIN LIU

Counsel

Fangda Partners

+86 755 8159 3956

kevin.liu@fangdalaw.com



PRACTICE AREAS

MR. LIU SPECIALIZES IN CAPITAL MARKETS, M&A, PRIVATE EQUITY AND GENERAL CORPORATE.

REPRESENTATIVE MATTERS AND CASES

Capital Markets

- Represented Mindray (300760.SZ), a leading global provider of medical devices and solutions, in its privatization, delisting, post-NYSE delisting restructuring, and IPO and A-share listing on the Shenzhen Stock Exchange's growth enterprise market in the largest ever A-share medical equipment project listing
- Represented iRay Technology (688301.SH) in its restructuring, IPO and A-share listing on the Shanghai Stock Exchange's Sci-tech Innovation Board in the largest IPO in the special equipment manufacturing industry on the Sci-tech Innovation Board and the first A-share listed company of medical core-component equipment
- Represented Huatai United Securities as the sole sponsor and underwriter in connection with Vazyme's IPO and listing on the Shanghai Stock Exchange's Sci-tech Innovation Board. Vazyme is a biotech company committed to R&D for technology and products focusing on functional proteins, such as enzymes, antigens, antibodies, and polymer organic materials
- Represented Aoshikang Technology (002913.SZ), a leading PCB manufacturing and R&D company in China, in its restructuring and IPO on the Shenzhen Stock Exchange's SME board

- Represented China Resources and provided strategic legal advice and transaction services in the acquisition of Vanke (000002.SZ) by external investors, the proposed share issue by Vanke to acquire assets of Shenzhen Metro, the corporate governance disputes with Vanke management, and the sale of approximately 15.31% shares in Vanke to Shenzhen Metro for approximately RMB 37.2 billion
- Represented Ninestar (002180.SZ) in its share issuance as part of an approximately RMB 2.25 billion acquisition of the print consumables assets held by Ninestar's controlling shareholder and in its USD 62.96 million cash acquisition of 100% equity of SCC, which is the world's third largest print consumables manufacturer
- Represented BTR, one of the leading enterprises in the global lithium battery anode material industry, in the largest IPO and listing on the NEEQ Select Market
- Represented Mindray (300760.SZ) in its restructuring of its animal medical assets and business for a future independent A-share IPO
- Represented OCT Group in a potential transaction to acquire the controlling interest in the controlling shareholder of an A-share listed real estate company through exercising preemption rights. The acquisition will trigger a general offer for the A-share listed real estate company and involve full legal due diligence on the A-share listed real estate company
- Represented CGWAMC in its rescue investment in A-share listed real estate company Yuetai Group (600393.SH) and in resolving Yuetai Group's debt crisis
- Represented the second largest shareholder of an A-share listed company in the shareholder's transfer of 10.08% shares in the A-share listed company through centralized competitive bidding with an agreement transfer
- Represented Ninestar (002180.SZ) and Huafu Fashion (002042.SZ) in their private placement of A shares
- Represented CA Cultural Technology Group in its Hong Kong IPO
- Represented Geneseeq Technology, Peak Sport, Fussen Technology and Landwin Medical in their ongoing restructuring and A-share IPO
- Represented Seine Technology, controlling shareholder of the A-share listed company Ninestar (002180.SZ), in its private offering of A-share exchangeable bonds of RMB 1 billion and RMB 5.2 billion
- Provided legal services on general corporate matters to several A-share listed companies, such as Mindray (300760.SZ), iRay Technology (688301.SH), Zhifei Biological (300122.SZ), Ninestar (002180.SZ) and BTR

(835185.NEEQ)

M&A/Private Equity

- Represented Shenzhen Major Industrial Investment Group in participating as an investor in the bankruptcy restructuring of Peking University Founder Group Co., Ltd. and in acquiring the controlling stake in Founder Microelectronics through the bankruptcy restructuring process
- Represented CPE in its multiple equity investments in the medical industry
- Represented Boyu Capital in its transfer of its 4.99% shares in Marisfrog, a well-known women's clothing brand company in China
- Represented Ant Financial in its equity investment in Galaxy Valley, a leading Chinese metro WIFI service provider
- Represented CMC Capital in its equity investments in a well-known beer production company and a well-known liquor sales company
- Represented Asia Investment Capital in its equity investment in Shandong Innovation
- Represented CMBI International in its equity investment in Happy Elements, a well-known casual game platform company in China
- Represented Rivocean Pharmaceutical, a hi-tech company integrated with sales, R&D and production of fine chemicals and API, in its RMB 100 million equity financing from Kanhoo Industry (300340.SZ), an A-share listed company

OTHER INFORMATION

Education

- Southwest University of Political Science & Law, LL.M., 2015
- Southwest University of Political Science & Law, LL.B., 2012
- Southwest University of Political Science & Law, B.A. in Management, 2012

Professional Qualification

- Admitted to practice in the PRC

Professional Background

Mr. Liu joined Fangda in 2016. Before joining the firm, he worked at a leading law firm.